Sahar Samimi, MD
@SaharSamimii
Followers
1K
Following
4K
Media
27
Statuses
569
PGY-2 @BCM_InternalMed| @ACCintouch IMRes|Research postdoc @MethodistHosp @MayoClinicCV| Co-host of @CardioTechx| Views mine
Houston, TX
Joined December 2021
Excited to have our case featured on @cardionerds and proud to represent @BCM_InternalMed & @BCMHeart! Thanks to @Lorraine_Masc, Dr. Basant Arya, @Dr_DanMD, and @RichardAFerraro for a great discussion-have a listen here! #CardioX #CardioTwitter
🚨 New #CardioNerds episode! 🚨 Ep 423: The Malignant Murmur - More Than Meets the Echo in NBTE @RichardAFerraro joins @SaharSamimii & @Lorraine_Masc with expert commentary by Dr. Basant Arya from @BCMHeart! 🎧 Listen now: https://t.co/70yujjZSvG
0
2
30
🚨 Hot off the press! Our new publication is out, check it out🔥 Supraventricular Tachycardia Burden on Ambulatory ECG Monitoring Predicts Recurrent Atrial Fibrillation Following Catheter Ablation for Atrial Fibrillation - American Journal of Cardiology https://t.co/xlS8OGK5Ef
3
6
22
Very proud of our research and clinical fellows @HMHCardioFellow for 15 presentations #TCT2025 @crfheart @WilliamZoghbi @AlanLumsdenMD @AlpeshShahMD @SLittleMD @NadeenFaza @DipanJShah @khurramn1 @almallahmo @SCAI @ACCinTouch
4
11
53
Hi #MedTwitter! I’m Pargol, a postdoc researcher @PennNeurology & an IMG from @TehUofMed, applying to #Neurology in #Match2026. Outside of Neurology, I enjoy traveling✈️, playing 🎹 & exploring nature🌳. Looking forward to connecting with peers & mentors. #NeuroMatch
12
22
198
Hi #MedTwitter! I’m Alireza, a postdoc researcher @PennCardiology & an IMG from @TehUofMed, applying to #InternalMedicine in #Match2026. Outside of medicine, I enjoy traveling✈️, playing tennis🎾, & exploring restaurants 🍕 Looking forward to connecting with peers & mentors!
13
25
201
‼️AI-powered automation for #echofirst quantification is here: EchoNet-Measurements, trained on nearly 878K annotations across 155K echo studies, delivers great performance against expert sonographers in internal and external validation cohorts. Congrats to @Yuki_Sahashi,
2
3
7
2
123
410
0
2
8
Happy to share our new paper out now in @AmJCardio In young adults (<50 y) on dialysis undergoing PCI, we found: 🔴 Higher bleeding events 🩸 🏥 Longer hospital stays ⚠️ Higher 1-year MACE ☠️ https://t.co/cTfpEKp2CG
0
10
42
#ESCCongress takeaways for #IMResidents : 🔹 REBOOT-CNIC: No benefit of BB post-MI EF≥40% 🔹 BB Meta-analysis: BB ↓ Death/MI/HF in EF 40–49% 🔹 AQUATIC: OAC alone > OAC+ASA 🔹 ALONE-AF: Safe to stop OAC ≥1y post-ablation 🔹 DIGIT-HF: Digitoxin ↓ Death/HFH #CardioX
0
4
33
🔴New Publication🔴 How does Tricuspid TEER compare with GDMT in patients with severe TR? ✅ ↓ Mortality ✅ ↓ HF hospitalizations ✅ Improved TR severity & NYHA class ❌ No excess stroke or PPM risk Check out the paper⬇️ @SachinGoelMD @HMethodistCV
#cardiotwitter
#MedX
6
10
43
The first RCT to show that use of a clinical risk score to guide care can improve hard cardiovascular outcomes. In PARTHENOPE, using the DAPT score to guide antiplatelet duration after PCI reduced net adverse events vs standard 12 month DAPT. Congrats @piccoloraf and team!
Live from #ESC2025: @piccoloraf presents results of PARTHENOPE - showing that a personalised post-PCI DAPT strategy was superior to a standard 12m approach, mainly driven by lower rate of ischaemic events, albeit with no major difference in bleeding events with the two strategies
5
16
88
🎯 2025 ESC Guideline Update Low-Flow, Low-Gradient AS + ↓EF 🫀 Old: Mandatory Dobutamine Stress Echo (DSE) 🆕 New: DSE not mandatory ❌ → Use CT Aortic Valve Calcium Score (AVCS) ✅ 📌 Severe AS: 👩 >1200 AU 👨 >2000 AU
2
112
340
Honored to be a part of the HI-PRO trial, presented today by my mentor @GregoryPiazza4 at #ESCCongress2025 Published @NEJM
https://t.co/DSAM4mstXB In provoked VTE & enduring risk, Extended low-dose apixaban vs placebo: ⬇️Risk of recurrent VTE with low risk of major🩸
nejm.org
The appropriate duration of anticoagulation for venous thromboembolism (VTE) in patients who have a transient provoking factor (e.g., surgery, trauma, or immobility) and concomitant enduring risk f...
Presented at #ESCCongress: In patients with provoked venous thromboembolism and ongoing risk factors, extended treatment with low-dose apixaban for 12 months resulted in a lower risk of recurrent VTE than placebo, with a low risk of major bleeding. Full HI-PRO trial results:
13
13
50
Darn it. There’s no editorial. Why? Because the heart failure community is stunned. They are speechless. No worries. You can read this (slightly biased) editorial for free on @theheartorg
https://t.co/0SuYQSvcJ3
#esccongress #esc2025
Presented at #ESCCongress: In patients with heart failure and reduced ejection fraction who were receiving guideline-directed medical therapy, digitoxin lowered the risk of death or hospitalization for heart failure as compared with placebo. Full DIGIT-HF phase 4 trial results:
11
33
164
New 2025 AHA/ACC BP Guidelines https://t.co/Q757Iu7CK6 my top ten takeaways 1)BP goal ≤130 /80, SBP ≤ 120 if risk for CVD (class 1) use single-pill combo to ↑ adherence & simplify Rx tighter control of HTN to lower dementia risk But avoid orthostatic hypotension (class1)
12
93
251
📢 Happy to share the paper "Innovations in #TAVR: The Latest in Device Technology" @JCM_MDPI @ErrolMoras @Lorraine_Masc @SaharSamimii @WKayaniMD @SyedZaidMD full text: https://t.co/ZipfruBPKs
0
1
3
A patient with advanced cardiac amyloidosis. PW Doppler of the hepatic vein is obtained in the subcostal view. What is the finding?
7
19
94
Important ACC document on pericarditis. Thanks to the pericardial team!
🆕 ACC scientific statement on the Dx & management of #pericarditis addresses diagnostic & therapeutic advances in acute & recurrent pericarditis & their complications, employing a multimodality imaging-guided therapeutic approach. Get the details: https://t.co/ypzikLih8M
#JACC
1
20
70